EnClear Therapies, a Cambridge, Mass.-based life sciences company developing device-based therapies for the treatment of neurodegenerative disease, raised $10m in Series A financing.
The round was led by 20/20 HealthCare Partners with participation from Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures. In conjunction with the funding, Hillel Bachrach, Managing Partner at 20/20 HCP, Jason Camm, Managing Director and Chief Medical Officer at Thiel Capital, and Zafrira Avnur, Chief Scientific Officer and Partner at Quark Venture will join EnClear’s Board of Directors.
The company intends to use the funds to move its therapeutic system to first-in-human clinical trial in Amyotrophic Lateral Sclerosis, as well as expand the platform into new applications and strategic partnerships.
Led by Anthony DePasqua, Chief Executive Officer and Co-founder, EnClear Therapies is a life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). The company’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).